Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis

Company Overview

Ono Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb. Beyond cancer immunotherapy, the company researches small‐molecule drugs and antibody therapeutics targeting various immunological pathways. It also produces in vitro diagnostics and laboratory reagents that support disease detection and treatment monitoring.

Ono Pharmaceutical operates primarily in Japan but has extended its reach globally through strategic alliances and licensing agreements. In overseas markets, the company collaborates with multinational partners to secure regulatory approvals and to manage manufacturing and distribution. Ono’s ongoing pipeline includes compounds in clinical trials for solid tumors, hematological malignancies and immune‐mediated disorders.

Key Stats

• Today's Range: $5.26 to $5.29
• 50-Day Range: $4.70 to $5.42
• 52-Week Range: $3.33 to $5.75
• Volume: 11,132 shs
• Average Volume: 26,562 shs
• Market Capitalization: N/A
• P/E Ratio: 1.15
• Dividend Yield: 314.59%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 5/17/2026
• Next Earnings (Estimated): 8/03/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OPHLY
• CIK: 940821
• Web: www.ono.co.jp
• Phone: (166) 263-5670
• Fax: N/A
• Employees: 3,761
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 1.15
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A